End-of-day quote
Korea S.E.
23:00:00 12/05/2024 BST
|
5-day change
|
1st Jan Change
|
6,780
KRW
|
+0.59%
|
|
+1.35%
|
-3.56%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
130,657
|
129,975
|
220,012
|
137,287
|
102,836
|
103,130
|
Enterprise Value (EV)
1 |
108,781
|
108,020
|
202,324
|
121,161
|
93,939
|
97,525
|
P/E ratio
|
-188
x
|
-198
x
|
-93.1
x
|
-44.5
x
|
-50.2
x
|
-42.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.36
x
|
9.52
x
|
16.9
x
|
9.63
x
|
6.42
x
|
5.94
x
|
EV / Revenue
|
7.79
x
|
7.91
x
|
15.5
x
|
8.5
x
|
5.87
x
|
5.61
x
|
EV / EBITDA
|
16,652
x
|
-323
x
|
-81.9
x
|
-35.3
x
|
-41.6
x
|
-81.4
x
|
EV / FCF
|
139
x
|
-171
x
|
-71.2
x
|
-55.8
x
|
-13
x
|
-48.6
x
|
FCF Yield
|
0.72%
|
-0.58%
|
-1.41%
|
-1.79%
|
-7.7%
|
-2.06%
|
Price to Book
|
3.69
x
|
3.65
x
|
6.51
x
|
4.44
x
|
3.54
x
|
4.1
x
|
Nbr of stocks (in thousands)
|
14,217
|
14,378
|
14,474
|
14,589
|
14,670
|
14,670
|
Reference price
2 |
9,190
|
9,040
|
15,200
|
9,410
|
7,010
|
7,030
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
13,958
|
13,653
|
13,046
|
14,258
|
16,008
|
17,373
|
EBITDA
1 |
6.533
|
-334.3
|
-2,469
|
-3,429
|
-2,257
|
-1,198
|
EBIT
1 |
-696.4
|
-1,191
|
-3,454
|
-4,505
|
-3,377
|
-2,631
|
Operating Margin
|
-4.99%
|
-8.72%
|
-26.47%
|
-31.59%
|
-21.1%
|
-15.14%
|
Earnings before Tax (EBT)
1 |
-604.5
|
-655.3
|
-2,352
|
-3,080
|
-2,045
|
-2,437
|
Net income
1 |
-604.5
|
-655.3
|
-2,352
|
-3,080
|
-2,045
|
-2,437
|
Net margin
|
-4.33%
|
-4.8%
|
-18.03%
|
-21.6%
|
-12.77%
|
-14.03%
|
EPS
2 |
-48.82
|
-45.72
|
-163.3
|
-211.6
|
-139.6
|
-166.1
|
Free Cash Flow
1 |
783.3
|
-630.5
|
-2,843
|
-2,171
|
-7,229
|
-2,006
|
FCF margin
|
5.61%
|
-4.62%
|
-21.79%
|
-15.22%
|
-45.16%
|
-11.55%
|
FCF Conversion (EBITDA)
|
11,990.77%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
21,875
|
21,954
|
17,688
|
16,126
|
8,897
|
5,605
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
783
|
-631
|
-2,843
|
-2,171
|
-7,229
|
-2,006
|
ROE (net income / shareholders' equity)
|
-2.51%
|
-1.84%
|
-6.78%
|
-9.51%
|
-6.82%
|
-9%
|
ROA (Net income/ Total Assets)
|
-1.39%
|
-1.76%
|
-5.2%
|
-6.83%
|
-5.13%
|
-4.09%
|
Assets
1 |
43,389
|
37,133
|
45,249
|
45,116
|
39,887
|
59,615
|
Book Value Per Share
2 |
2,493
|
2,477
|
2,334
|
2,122
|
1,978
|
1,714
|
Cash Flow per Share
2 |
1,849
|
1,404
|
1,086
|
561.0
|
380.0
|
154.0
|
Capex
1 |
203
|
626
|
891
|
725
|
4,572
|
1,672
|
Capex / Sales
|
1.45%
|
4.59%
|
6.83%
|
5.09%
|
28.56%
|
9.62%
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.56% | 72.74M | | -14.06% | 76.62B | | +15.03% | 8.4B | | +26.62% | 3.76B | | +18.24% | 1.65B | | -7.99% | 1.53B | | -22.43% | 1.3B | | -3.61% | 1.25B | | -9.08% | 1.19B | | +5.25% | 1.1B |
Veterinary Drugs
|